Parexel Appoints Imogene Grimes to Vice President of Data Sciences Strategic Services
Parexel hires Imogene Grimes, a leading biostatistician with more than 25 years of experience, as vice president of data sciences strategic services.
Boston, MA-April 30, 2008-Parexel, a leading global biopharmaceutical services organization, has appointed Imogene Grimes to vice president of data sciences strategic services. Dr. Grimes, a leading biostatistician with more than 25 years of experience, is contributing to the continued expansion of Parexel's data science services, including data management, biostatistics, and applications of information technology to the clinical development process. Her responsibilities include advising clients on clinical study design, analysis methodology, and related regulatory guidelines. Dr. Grimes provides support for strategic data services, such as preparation of integrated data files suitable for registration packages and preparation of electronic submissions, compliant with regulatory expectations.
"The biopharmaceutical industry is undertaking more complex clinical research such as using adaptive designs with the potential to detect safety and efficacy signals earlier. Dr. Grimes will bring experience with advanced statistical methods to Parexel, which we believe will be a tremendous asset to our clients in bringing novel treatments to patients sooner,” said Mark A. Goldberg, MD, president of clinical research services and Perceptive Informatics at Parexel.
"Parexel has one of the industry's largest and most deeply expert data sciences departments,” said Barbara Tardiff, MD, corporate vice president of data sciences, clinical research services, Parexel. "We look forward to the contributions Dr. Grimes will make to further strengthen and expand our strategic data and informatics capabilities for clients globally as well as supporting our e-submissions strategies.”
Prior to joining Parexel, Dr. Grimes served as vice president, statistics, data management and informatics at Regeneron Pharmaceuticals, where she provided statistical and data management expertise for all phases of drug development research. Previously, she was vice president statistics and data management at Yamanouchi Pharma America, now Astellas Pharma, and held senior management positions at Pfizer and GlaxoSmithKline.
Dr. Grimes holds a Ph.D. in Biostatistics from the University of North Carolina at Chapel Hill, and Master's and Bachelor's degrees from the University of North Carolina at Greensboro. A focus of Dr. Grimes' career has been regulatory submissions of marketing applications using electronic media and in particular ensuring an understanding of regulatory expectations for statistics and data management. She currently serves as a board member of the Data Quality Research Institute, and is a member of several industry organizations including the American Statistical Association and The International Biometric Society. Dr. Grimes has presented several training courses and has authored numerous articles on data management and statistics topics.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
